Molecular basis of cis-diamminedichloroplatinum(II) resistance: A review

Journal of the Formosan Medical Association

Volumn 95, Issue 12, 1996, Pages 893-900

  Chao, Chuck C K ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

chemotherapy; cisplatin; cisplatin damaged DNA recognition proteins; DNA repair; drug resistance; free radical; signal modulator

Indexed keywords

CISPLATIN;

CANCER; CANCER CHEMOTHERAPY; DNA DAMAGE; DNA REPAIR; DRUG EFFECT; HUMAN; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION;

ANIMALS; CISPLATIN; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DNA ADDUCTS; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; FREE RADICAL SCAVENGERS; HUMANS; PROTEIN BINDING; PROTEIN KINASE C; SIGNAL TRANSDUCTION;

EID: 0030513624     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (94)

1. Rosenberg B, Van Camp L, Krigas T: Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 1965;205:698-9.
2. Rosenberg B: Fundamental studies with cisplatin. Cancer 1985;5:2303-16.
3. Loehrer PJ, Einhorn LH: Cisplatin. Ann Intern Med 1984;100:704-13.
4. Lippard S: Chemistry and molecular biology of platinum anticancer drugs. Pure Appl Chem 1987;59:731-42.
5. Bellon S, Coleman J, Lippard S: DNA unwinding produced by site-specific intrastrand cross-links of the antitumor drug cis-diamminedichloroplatinum(II). Biochemistry 1991;30:8026-35.
6. Fichtinger-Schepman AMJ, van der Veer JL, den Hartog JHJ, et al: Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification and quantitation. Biochemistry 1985;24: 707-13.
7. Eastman A: Reevaluation of interaction of cis-dichloro(ethylenediammine)-platinum(II) with DNA. Biochemistry 1986;25:3912-5.
8. Eastman A, Schulte N, Sheibani N, et al: Mechanisms of resistance to platinum drugs. In: Nicolini M, ed. Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Boston: Martinus Nijhoff, 1988:248-54.
9. Knox R, Friedlos F, Lvdall D, et al: Mechanism of cytotoxicity of anticancer platinum drugs: evidente that cis-diamminedichloroplatinum(II) and cis-diammine (1,1cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Canter Res 1986;46:1972-9.
10. Sorenson CM, Eastman A: Mechanism of cis-diamminedichloroplatinum(II)-induced cytotoxicity: role of G2 arrest and DNA double strand breaks. Cancer Res 1988;48:4484-8.
11. Andrew PA, Howell SB: Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 1990;2:35-43.
12. Timmer-Bosscha H, Mudler NH, de Vries EGE: Modulation of cis-diamminedichloroplatinum(II) resistance: a review. Br J Cancer 1992;66:227-38.
13. Chu G: Cellular response to cisplatin: the roles of DNA-binding proteins and DNA repair. J Biol Chem 1994;269:787-90.
14. Bernal S, Speak J, Boeheim K, et al: Reduced membrane protein associated with resistance of human squamous carcinoma cells to methotrexate and cis-platinum. Mol Cell Biochem 1990;95:61-70.
15. Kawai K, Kamatani N, Georges E, et al: Identification of a membrane glycoprotein overexpressed in marine lymphoma sublines resistant to cis-diamminedichloroplatinum(II). J Biol Chem 1990;265:13137-42.
16. Deuchars K, Ling V: P-glycoprotein and multidrug resistance in cancer chemotherapy. Semin Oncol 1989;16:156-65.
17. Chao CCK, Huang YT, Ma CM, et al: Overexpression of glutathione S-transferase and elevated thiol pools in a multidrug-resistant human colon cancer cell line. Mol Pharmacol 1992;41:69-75.
18. Wallner KE, Degregorio MW, Li GC: Hyperthermic potentiation of cis-diamminedichloroplatinum(II) cytotoxicity in Chinese hamster ovary cells resistant to the drug. Cancer Res 1986;46:6242-5.
19. Mann SC, Andrews PA, Howell SB: Modulation of cis-diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells. Int J Cancer 1991;48:866-72.
20. Hoffmann J, Doppler W, Jakob A, et al: Enhancement of the antiproliferative effect of cis-diamminedichloroplatinum(II) and nitrogen mustard by inhibitors of protein kinase C. Int J Cancer 1988;42:382-8.
21. Rasu A, Teicher BA, Lazo JS: Involvement of protein kinase C in phorbol ester-induced sensitization of HeLa cells to cis-diamminedichloroplatinum(II). J Biol Chem 1990;265:8451-7.
22. Ikeda H, Nakano G, Nagashima K, et al: Verapamil enhancement of antitumor effect of cis-diamminedichloroplatinum(II) in nude mouse-grown human neuroblasloma. Cancer Res 1987;47:231-4.
23. Onoda JM, Nelson KK, Taylor JD, et al: In vitro characterization of combination antitumor chemotherapy with calcium channel blockers and cis-diamminedichloroplatinum(II). Cancer Res 1989;49:2844-50.
24. Kikuchi Y, Oomori K, Kizawa I, et al: Enhancement of antineoplastic effects of cisplatin by calmodulin antagonists in nude mice bearing human ovarian carcinoma. Cancer Res 1987;47:6459-61.
25. Perez RP, Handel LM, Schilder RJ, et al: Potentiation of cisplatin cytotoxicity by trifluoperazine, a calmodulin inhibitor. Proc Am Assoc Cancer Res 1990;31:403.
26. Meister A, Anderson M: Glutathione. Ann Rev Biochem 1983;52:711-60.
27. Ishikawa T, Ali-Osman F: Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. J Biol Chem 1993;268:20116-25.
28. Ishikawa T, Wright CD, Ishizuka H: GS-X pump is functionally overexpressed in cis-diamminedichloroplatinum(II)-resistant human leukemia HL-60 cells and down-regulated by cell differentiation. J Biol Chem 1994;269:29085-93.
29. Lai GM, Ozols RF, Young RC, et al: Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines. J Natl Cancer Inst 1989;81:535-9.
30. Hamer D: Metallothionein. Ann Rev Biochem 1986;55: 913-51.
31. Andrew PA, Murphy MP, Howell SB: Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol 1987;19:149-54.
32. Andrews PA, Murphy MP, Howell SB: Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res 1985;45:6250-3.
33. Kelley SL, Basu A, Teicher BA, et al: Overexpression of metallothionein confers resistance to anticancer drugs. Science 1988;241:1813-5.
34. Schilder R, Hall L, Monks A: Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. Int J Cancer 1990;45:416-22.
35. Szymkowski D, Yarema K, Essigmann J, et al: An intrastrand d (GpG) platinum crosslink in duplex M13 DNA is refractory to repair by human cell extracts. Proc Natl Acad Sci USA 1992;89:10772-6.
36. Eastman A, Schulte N: Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). Biochemistry 1988;27:4730-4.
37. Parker R, Eastman A, Bostick-Bruton F: Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest 1991;87:772-7.
38. Chao CCK: Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum(II) in cervix carcinoma HeLa cells: relation to DNA repair. Mol Pharmacol 1994;45:1137-44.
39. Sheibani N, Jennerwein M, Eastman A: DNA repair in cells sensitive and resistance to cis-diamminedichloroplatinum(II): host cell reactivation of damaged plasmid DNA. Biochemistry 1989;28:3120-4.
40. Lai GM, Ozols RF, Smyth J: Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. Biochem Pharmacol 1988;37:4597-600.
41. Chu G, Chang E: Cisplatin-resistant cells express increased levels of a factor that recognizes damaged DNA. Proc Natl Acad Sci USA 1990;87:3324-7.
42. Chao CCK, Lee LY, Lin-Chao S: Enhanced host cell reactivation of damaged plasmid DNA in HeLa cells resistant to cis-diamminedichloroplatinum(II). Cancer Res 1991;51:601-5.
43. Zhen W, Link C, O'Connor P, et al: Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol 1992;12:3689-98.
44. Ciccarelli R, Solomon M, Yarshavsky A, et al: In vivo effects of cis- and trans-diamminedichloroplatinum(II) on SY40 chromosomes: differential repair, DNA-protein cross-linking, and inhibition of replication. Biochemistry 1985;24:7533-40.
45. Masuda H, Ozols RF, Lai CM, et al: Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum(II) in human ovarian cancer cell lines. Cancer Res 1988;48:5713-6.
46. Chao CCK, Lee YL, Lin-Chao S: Phenotypic reversion of cisplatin resistance in human cells accompanies reduced host cell reactivation of damaged plasmid. Biochem Biophys Res Commun 1990;170:851-9.
47. Trujillo JM, Yang LY: Synergism of 1-β-arabinofuranosylcytosine and cis-diamminedichloroplatinum in their lethal efficacies against seven established cancer cell lines of gastrointestinal origin. Anticancer Res 1989;9:197-202.
48. Scanlon KJ, Newman EM, Lu Y, et al: Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 1986;83:8923-5.
49. Eder JP, Teicher BA, Holden SA, et al: Novobiocin enhances alkylating agent cytotoxicity and DNA interstrand cross-links in a murine model. J Clin Invest 1987;79:1524-8.
50. Chen G, Pan Q: Potentiation of the antitumour activity of cisplatin in mice by 3-aminobenzamide and nicotinamide. Camer Chemother Pharmacol 1988;22:303-7.
51. Meyn RE, Corry PM, Fletcher SE, et al: Thermal enhancement of DNA damage in mammalian cells treated with cis-diamminedichloroplatinum. Cancer Res 1980;40:1136-9.
52. Allen ED, Natal RB: Effect of α-difluoromethyl-ornithine alone and in combination with doxorubicin hydrochloride, cis-diamminedichloroplatinum(II), and vinblastine sulfate on the growth of P3J cells in vitro. Cancer Res 1986;46:3550-5.
53. Chu G, Chang E: Xeroderma pigmentosum group E cells lack a nuclear factor that binds to damaged DNA. Science 1988;242:564-7.
54. Chao CCK, Huang SL, Huang H, et al: Cross resistance to UY radiation of a cisplatin-resistant human cell line: overexpression of cellular factors that recognize UV-modified DNA. Mol Cell Biol 1991;2075-80.
55. Hwang BJ, Chu G: Purification and characterization of a human protein that binds to damaged DNA. Biochemistry 1993;32:16:1657-66.
56. Kataoka H, Fujiwata Y: UV damage-specific DNA-binding protein in xeroderma pigmentosum complementation group E. Biochem Biophys Res Commun 1991;175:1139-43.
57. Chao CCK: Damage-recognition proteins as a potential indicator of DNA damage-mediated sensitivity or resistance of human cells to ultraviolet radiation. Biochem J 1992;282:203-7.
58. Keenev S, Wein H, Linu S: Biochemical heterogeneity in xeroderma-pigmentosum complementation group E. Mutat Res 1992;273:49-56.
59. Hwang BJ, Liao JC, Chu G: Isolation of a cDNA encoding a UV-damaged DNA binding factor defective in xeroderma pigmentosum group E cells. Mutat Res 1996;362:105-17
60. Takao M, Abramir M, Moos M, et al: A 127 kDa component of a UV-damaged DNA-binding complex, which is defective in some xeroderma pigmentosum group E patients, is homologous to a slime mold protein. Nucleic Acids Res 1993;21:4111-8.
61. Mu D, Park CH, Matsunaga T, et al: Reconstitution of human DNA repair excision nuclease in a highly defined system. J Biol Chem 1995;270:2415-8.
62. He Z, Henricksen LA, Wold MS, et al: RPA involvement in the damage-recognition and incision steps of nucleotide excision repair. Nature 1995;374:566-9.
63. Matsuda T, Saijo M, Kuraoka I, et al: DNA repair protein XPA binds replication protein A (RPA). J Biol Chem 1995;270:4152-7.
64. Van Duin M, deWit J, Odijk H, et al: Molecular characterization of the human excision repair gene ERCC-1: cDNA cloning and amino acid homology with the yeast DNA repair gene RAD10. Cell 1986;44:913-23.
65. Dabholkar M, Bostick-Bruton F, Weber C, et al: ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 1992;84:1512-7.
66. Matsunaga T, Mu D, Park CH, et al: Human DNA repair excision nuclease: analysis of the roles of the subunits involved in dual incisions by using anti-XPG and anti-ERCC1 antibodies. J Biol Chem 1995;270:20862-9.
67. Li L, Peterson A, Lu X, et al: Mutations in XPA that prevent association with ERCC1 are defective in nucleotide excision repair. Mol Cell Biol 1995;15:1993-8.
68. Sancar A: Excision repair in mammalian cells. J Biol Chem 1995;270:15915-8.
69. Sklar M: Increased resistance to cis-diamminedichloroplatinum(II) in NIH3T3 cells transformed by ras oncogenes. Cancer Res 1988;48:793-7.
70. Scanlon KJ, Lu Y, Kashani-Sabet M, et al: Mechanisms for cisplatin-FUra synergism and cisplatin resistance in human ovarian carcinoma cells both in vitro and in vivo. In: Rustum Y, McGuire JJ, eds. The Expanding Role of Folates and Flouropyrimidines in Cancer Chemotherapy. New York: Plenum, 1988:127-35.
71. Scanlon KJ, Kashani-Sabet M, Miyachi H, et al: Molecular basis of cisplatin resistance in human carcinomas: model systems and patients. Anticancer Res 1989;9:1301-12.
72. Scanlon KJ, Kashani-Sabet M, Sowers LC: Overexpression of DNA replication and repair enzymes in cisplatin-resistant human colon carcinoma HCT8 cells and circumvention by azidothymidine. Cancer Comm 1989;1:269-75.
73. Isonishi S, Andrews PA, Howell SB: Increased sensitivity to cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells in response to treatment with 12-O-tetradecanoylphorbol-13-acetate. J Biol Chem 1990; 265:3623-7.
74. Toney JH, Donahue BA, Kellett FJ, et al: Isolation of cDNAs encoding a human protein that hinds selectively to DNA modified by the anticancer drug cis-diamminedichloroplatinum(II). Proc Natl Acad Sci USA 1989;86:8328-32.
75. Chao CCK, Huang SL, Lee LY, et al: Identification of inducible damage-recognition proteins that are overexpressed in HeLa cells resistant to cis-diamminedichloroplatinum(II). Biochem J 1991;277: 875-8.
76. McLaughlin K, Coren G, Masters J, et al: Binding activities of cisplatin-damage recognition proteins in human tumour cell lines. Int J Cancer 1993;53:662-6.
77. Bruhn SL, Pil PM, Essigmann JM, et al: Isolation and characterization of human cDNA clones encoding a high mobility group box protein that recognizes structural distortions to DNA caused by binding of the anticancer agent cisplatin. Proc Natl Acad Sci USA 1992;89:2307-11.
78. Pil PM, Lippard SJ: Specific binding of chromosomal protein HMG1 to DNA damaged bv the anticancer drug cisplatin. Science 1992;256:234-7.
79. Hughes EN, Engelsberg BN, Billings PC: Purification of unclear proteins that bind to cisplatin-damaged DNA: identity with high mobility group proteins 1 and 2. J Biol Chem 1992;267:13520-7.
80. Chow CS, Bares CM, Lippard SJ: A single HMG domain in high-mobility group 1 protein binds to DNAs as small as 20 base pairs containing the major cisplatin adduct. Biochemistry 1995;34:2956-64.
81. Jantzen HM, Admon A, Bell SP, et al: Nucleolar transcription factor hUBF contains a DNA-binding motif with homolog to HMG proteins. Nature 1900;344:830-6.
82. Treiber DK, Zhai X, Jantzen HM, et al: Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor). Proc Natl Acad Sci USA 1994;91:5672-6.
83. Lilly DMJ: HMG has DNA wrapped up. Nature 1992;357:282-3.
84. Baxevnis AD, Landsman D: The HMG-1 box protein family: classification and functional relationships. Nucleic Acids Res 1995;23:1019-29.
85. Brown SJ, Kellett PJ, Lippard SJ: Ixr1, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin. Science 1993;261:603-5.
86. Sancar G: DNA photolyases: physical properties, action mechanism, and roles in DNA repair. Mutat Res 1990;236:147-60.
87. Patterson M, Chu G: Evidence that xeroderma pigmentosum cells from complementation group E are deficient in a homolog of yeast photolyase. Mol Cell Biol 1989;9:5105-12.
88. Li YF, Kim ST, Sancar A: Evidence for lack of DNA photoreactivating enzyme in humans. Proc Natl Acad Sci USA 1993;90:4389-93.
89. Chao CCK: Lack of enzymatic photoreactivation in HeLa cell-free extracts. FEBS Lett 1993;336:411-6.
90. Donahue BA, Augot A, Bellon M, et al: Characterization, of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin. Biochemistry 1990;29:5872-80.
91. Fox ME, Feldman BJ, Chu G: A novel role for DNA photolyase: binding to DNA damaged by drugs is associated with enhanced cytotoxicity in Saccharomyces cerevisae. Mol Cell Biol 1994;14:8071-7.
92. McClay EF, Albright KD, Jones JA, et al: Modulation of cisplatin resistance in human malignant melanoma cells. Cancer Res 1992;52:6790-6.
93. McClay EF, Albright KD, Jones JA, et al: Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells. Cancer Res 1993;53:1571-6.
94. Teicher B, Herman T, Holden S, et al: Tumor resistance to atkylating agents conferred by mechanisms operative only in vivo. Science 1990;247:1457-61.